NPHLA Daily
NPHLA Daily
Wednesday, October 7, 2026 · 4-minute read
Good morning. Here is what changed across metabolic medicine, pharmacy regulation, aesthetics and healthcare technology since yesterday — every item linked to its source.
Top development today
What changed today in Aesthetics & Longevity: 1 trial update, 1 new study
NPHLA tracked 2 new official records on this desk today: 1 trial update, 1 new study. First: Trial status changed to “Withdrawn”: SERCABOT (Serratus Plane Block (SPB) Versus Capsaïcine Versus Botox-A for Chronic Neuropathic Pain in Post-mastectomy Syndrome)
Metabolic signal
What changed today in Metabolic: 1 new study
NPHLA tracked 1 new official record on this desk today: 1 new study. First: New research in Peptides: “Bidirectional Pharmacology of GIP Receptor Targeting in Obesity: Historical Foundations, Mechanistic Divergence, and Translational Boundaries”.
Aesthetics & Longevity signal
Trial status changed to “Withdrawn”: SERCABOT (Serratus Plane Block (SPB) Versus Capsaïcine Versus Botox-A for Chronic Neuropathic Pain in Post-mastectomy Syndrome)
Phase 2, Centre Oscar Lambret. Previously “Recruiting”. Conditions: Post-Mastectomy Neuropathic Pain Syndrome. Interventions: Capsaicin 8% Patch; Serratus Plane Block; Botulinum Toxin A. Investigational: trial-stage therapies are not…
AI & Technology signal
What changed today in AI & Technology: 1 new study
NPHLA tracked 1 new official record on this desk today: 1 new study. First: New research in JMIR research protocols: “Evaluation of Ambient Voice Technology in the National Health Service in England: Protocol for a Phase 2 Study”.
One thing worth watching
Comments close: Agency Information Collection Activities; Proposed Collection; Comment Request; Registration of Human Drug Compounding Outsourcing Facilities Under the Federal Food, Drug, and…
October 29, 2026 — verified from the Federal Register comments_close_on.
5 things to know
- What changed today in Aesthetics & Longevity: 1 trial update, 1 new study
- What changed today in Metabolic: 1 new study
- What changed today in AI & Technology: 1 new study
- Trial status changed to “Withdrawn”: SERCABOT (Serratus Plane Block (SPB) Versus Capsaïcine Versus Botox-A for Chronic Neuropathic Pain in Post-mastectomy Syndrome) (ClinicalTrials.gov (U.S. National Library of…
- Evaluation of Ambient Voice Technology in the National Health Service in England: Protocol for a Phase 2 Study (JMIR research protocols)
Compiled by NPHLA Intelligence from published briefings and official records. Professional information only — not medical or legal advice. Our standards.